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Abstract
Endometrial cancer is the most common malignancy of the female pelvis. New concepts in endometrial cancer
treatment emphasize the value of MRI as a major predictor of lymph node metastasis and tumour recurrence. MRI
findings aid in triaging patients for a more tailored therapeutic regimen.
This review discusses the value of MRI in the preoperative assessment of endometrial cancer and provides a
practical approach how to image and report endometrial cancer. Practical tips are provided how to increase the
diagnostic accuracy in staging of endometrial cancer and how to avoid pitfalls.
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Background
Endometrial carcinoma is the leading malignant tumour of
the female genital tract in industrialized countries. Over the
last decade the annual incidence has remained stable with
an estimated 25.1 cases per 100. 000 women [1]. The vast
majority of endometrial cancer is diagnosed at an early
stage with atypical uterine bleeding in postmenopausal age.
The 5-year overall survival is 81.7 %, but it varies broadly
from 20 to 91 % for different tumour histologies and stages
[2, 3]. For radiologists it is important to incorporate the
histopathological subtypes I or II in their reporting. These
subtypes differ not only with regard to histology and risk
factors, but also in clinical features, including stage at pres-
entation, risk of dissemination and in recurrence rate. Type
I accounts for 80–85 % of endometrial cancers, it is
estrogen-responsive and has a favorable prognosis [4]. His-
tologically it constitutes endometrioid adenocarcinomas
grade I and II. Endometrial cancer type II is characterized
by rapid tumour progression and a biological behavior
often similar to ovarian cancer. Histologically it comprises
endometroid cancer grade 3, and other rare histologies, e.g.
serous cancers, clear cell cancers and carcinosarcoma/
mixed Müllerian tumours [5]. Surgical staging with total ab-
dominal hysterectomy and bilateral salpingo-oophorectomy
has been the mainstay of therapy in endometrial cancer.
Findings at staging also guide subsequent adjuvant treat-
ment. There is ongoing controversy on the value of routine
pelvic and para-aortic lymphadenectomy in early
endometrial cancer surgery [5]. Recently a trend towards
tailored lymphadenectomy is seen in many cancer centers,
as it has been shown that only patients with intermediate or
high risk endometrial cancer benefit from pelvic and para-
aortic lymphadenectomy [5, 6].
Review
Role of MRI in the diagnostic work-up of endometrial
cancer
Internationally, the practice of preoperative MRI evalu-
ation of patients with endometrial cancer differs widely.
According to the American College of Radiology (ACR)
appropriateness criteria “MRI should be the preferred
imaging modality for treatment planning, when avail-
able”, as it allows best overall assessment of the disease
[7]. The National Comprehensive Cancer Network
(NCCN) guidelines advise MRI when cervical invasion is
suspected but also in pre-treatment evaluation of type II
endometrial cancer [8]. The European Society of Uro-
genital Radiology guidelines recommend MRI in high
and intermediate risk cancers, in suspected advanced
disease and before lymph node sampling [9]. In 2015 a
multidisciplinary European expert consensus meeting on
endometrial cancer advised MR imaging in apparent
stage I endometrial cancer to assess the depth of myo-
metrial invasion, when tailored lymph node dissection is
performed. However, alternatively, expert ultrasound
(US) and/or intraoperative pathological exams are other
options [5]. Patients can be divided into three risk cat-
egories based upon histopathological tumour type and
grade and depth of myometrial invasion [10]. There is
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increasing evidence that when findings of staging MRI
and hysteroscopic biopsy are combined, women at high
risk of lymph node metastases can be identified pre-
operatively [10–13]. In one study this yielded an accur-
acy of 81 % and was superior to combined transvaginal
sonography (TVS) and hysteroscopic biopsy [13]. An-
other central preoperative finding in MRI is cervical
stromal invasion. This requires modification of the sur-
gery technique including radical hysterectomy and pelvic
and abdominal lymphadenectomy. Combined radiother-
apy treatment is performed in most centers [5, 11]. MRI
findings also contribute in triaging and guiding neoadju-
vant therapy in advanced endometrial cancer in multi-
disciplinary consensus conferences [5, 11].
Indications
At our institution MRI indications to assess endometrial
cancer include: histologically proven endometrial cancer
with histologies or US findings suggesting intermediate or
high risk, sonographically suspected endometrial cancer
and vaginal stenosis (without access for biopsy), uterine
cancer of unknown origin (endometrial versus endocervi-
cal), central pelvic mass likely malignant, rapidly enlarging
uterus in postmenopausal age, and in advanced metastatic
cancer spread and suspected uterine neoplasm in CT.
Imaging
Imaging technique
Measures undertaken to reduce bowel motion and thus
improve image quality include fasting for at least 4 h be-
fore the exam, injection of antiperistaltic drugs (hyoscine
butylbromide preferably intramuscularly or glucagon
intramuscularly) before the exam, and tight wrapping of
a belt around the pelvis and abdomen. Anxious patients
are positioned with feet first. As a full bladder may cause
artifacts and is barely tolerated by most patients, the
bladder should be emptied at about 30 min or just be-
fore the exam.
A phase array coil is used for pelvic and abdominal
imaging. Correct positioning of the coil with regard to
pelvic anatomy is pivotal, especially when small FOV
and fat saturation techniques are used. Fat saturation
bands are applied to eliminate motion artifacts from the
anterior abdominal wall (Fig. 1).
A localizer in 3 planes provides anatomical details, par-
ticularly position and size of the uterus and serves for
planning the diagnostic images. The key imaging sequence
to assess the uterus is T2WI. Thus, 3 planes of T2WI will
allow definition of size, location, extent, and morphology
of endometrial cancer. This is best done by choosing a sa-
gittal T2WI displaying the tumour within the uterine cav-
ity or the dilated uterine cavity. Two additional planes
parallel and perpendicular to the uterine cavity are then
performed (Fig. 1). In case of tumour extending to the cer-
vix a complementary section perpendicular to the cervical
canal should be included. This serves to assess cervical
stromal extension, and is necessary in small tumour size
or equivocal findings. If the tumour is unequivocally thin-
ning the cervix already in the sagittal view, such a plane
can be omitted. Transaxial T1WI facilitate depiction of
pelvic lymph nodes and assist in defining the quality of
fluid filled distension of the uterine cavity and the morph-
ology, particularly of hemorrhagic tumour components.
Our routine protocol always includes DWI of the pelvis,
as this technique is fast and will render valuable informa-
tion for tumour detection, differentiation of tumour from
benign lesions and will alert to pelvic lymph nodes as well
as tumour spread beyond the uterus. The sequence should
be acquired in the identical angulation as T2WI (Fig. 2).
Some authors advise DWI in 2 planes, as these will allow
both complete coverage of the tumour and the pelvis in-
cluding the pelvic lymph node status [14]. Lymph nodes
can easily be detected on DWI but the DWI/ADC can’t
distinguish between benign and malignant lymph nodes,
additional morphologic criteria are needed for this differ-
entiation. The value of Gd T1WI is problem solving in
equivocal findings of tumour spread, typically of the depth
Fig. 1 Basic imaging technique in stage Ia endometroid cancer. Anterior sat bands (*) are used to reduce artifacts from breathing. Sagittal T2WI
(a) render an overview of the pelvis including the distal lumbar region. The image displaying the distended uterine cavity is used as reference for
sections perpendicular (b) and along the long uterine axis (c). DWI are used in same plane as in b. The tumour displays intermediate SI on T2WI
and shows restricted diffusion
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Fig. 2 Value of complementary DWI and GdT1 to assess myometrial invasion. Endometrial cancer expanding the uterine cavity and extending to
the upper cervix (arrow) is seen on sagittal T2WI (a). The planes for assessing myometrial and cervical invasion are perpendicular to the long axis
(dotted and dashed lines, a). T2WI perpendicular to the uterine cavity (b) demonstrates thinning of the myometrium. Deep myometrial invasion
can be confirmed by DWI (b = 1000) (c) and (d) and by Gd T1 FS (e)
Table 1 MR protocol for evaluation of endometrial cancer



















T2 FS DWI Gd Dixon
3D FSPGR
Range pelvis pelvis pelvis pelvis pelvis pelvis pelvis abdomen abdomen abdomen
Sections 26 29 29 27 28 55/slab 150 46 38 150
TR 3100 3500 3500 540 3195 3 3,7 2177 4429 3,2




perp.a parallel a perpa sagittal transaxial transaxial
Slice thickness
(mm)
3,5 3 3 6 5 4 1.5 5 8 1,5
Gap (mm) 0,35 0,3 0,3 6 0,5 0,5 0,8
FOV (mm) 260 210 210 250 300 250 350 280 300 350
B values 0,800,1200 0,800,1200
phases 4: un-enhanced, at 1,
1.45 and 2.10 min
Matrix 580 ×
260
280 × 261 280 × 261 276 ×
257
100 × 98 168 × 167 236 × 158 252 × 168 116 × 124 236 × 158
Acquisition
time (min)
3:36 3:30 3:30 2:16 3:28 15 s each 22 s 3:30 3:40 0:19
aAngulation along uterine axis
NB: In pelvic and abdominal series contiguous coverage is necessary
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of myometrial invasion and of presence of cervical inva-
sion. If the study is performed under radiologist supervi-
sion and if based on the basic sequences T2WI and DWI
tumour extension can be unequivocally defined additional
GdT1WI is not necessary. Otherwise, dynamic contrast
enhancement sequences are performed to improve the
conspicuity of tumour extension and presence of metasta-
ses. Gadolinium improves tumour –myometrium discrim-
ination, with best contrast gained at about 120–180 s after
intravenous (IV) contrast application (9) (Fig. 2). Optimal
cervical contrast may be acquired in a later phase with a
delay of 4 min after IV contrast media [15]. Of note, in ad-
vanced peritoneal disease and ascites Gd T1WI should
not be performed with a delay longer than 5 min as ascites
may show delayed contrast uptake and thus peritoneal
metastases may be obscured [16]. Retroperitoneal nodes,
kidneys and liver should also be included in the staging
exam. We perform transaxial DWI and Gd FS T1WI if
contrast media were administered, otherwise T2STIR se-
quences. Technical details (3 T) of the staging protocol
are summarized in Table 1.
Imaging findings
Staging of endometrial cancer
Endometrial cancer is staged surgico-pathologically ac-
cording to the FIGO system, the world wide most com-
monly used classification, or the TNM system. The 2009
revised FIGO staging classification has facilitated radio-
logical analysis of tumour spread within the uterus as
major challenges for radiological assessment have been
eliminated [17, 18]. The recent FIGO system and corre-
sponding MRI findings are summarized in Table 2.
Depth of myometrial invasion (less or≥ than 50 % myo-
metrial invasion) divides stages IA from stage IB (Figs. 1 and
2). Tumour growth along the endocervix but without cer-
vical stromal extension is also defined as stage I. For assign-
ing stage II cervical stromal invasion must be present. Stage
IIIA defines tumour spread to adjacent uterine serosa or ad-
nexa (Fig. 3). In Stage IIIB vaginal or parametrial involve-
ment is present. Stage IIIC is characterized by lymph node
metastases, either in the pelvis (IIIC1) or in the paraaortic
region (IIIC2) (Fig. 4). Tumour invasion into bladder or
bowel mucosa classifies as stage IVA. Stage IVB is classified
in distant metastases or inguinal lymph node involvement.
Key points in MR staging of endometrial cancer
 Endometrial cancer is typically mildly hyperintense
on T2-WI compared to normal myometrium [19]
(Fig. 1). Subtype II tends to exhibit inhomogeneous
morphology with areas of haemorrhage and necrosis
and is commonly diagnosed with deep myometrial
invasion (Fig. 3).
 Most tumours arise from the fundus and display
exophytic expansion. Diffuse infiltrative growth is
rarely found and characterized by diffuse
myometrial thickening.
 Evaluation of the uterus at least in 2 planes using
T2WI (maximal 4 mm slice thickness) along the
uterine axis is mandatory to define the depth of
myometrial invasion [9].
Table 2 FIGO Staging of endometrial carcinoma and adapted MRI findingsa
FIGO
Stage
Tumour invasion MR imaging findings
I Tumour confined to uterus
IA ≤50 % of myometrium Abnormal SI in endometrial cavity or confined to inner half of myometrium
IB >50 % of myometrium Extends into the outer half of myometrium
II Cervical stromal invasion, but not extension beyond
uterus
Disruption or focal thinning of cervical stroma
III Local or regional spread
IIIA Serosa of uterus and/or adnexa Disruption or irregular uterine contour caused by tumour; ovarian nodular tumour
IIIB Vagina or parametria Direct tumour extension of upper vagina or/and parametrial tissues
IIIC Metastases to pelvic and/or paraaortic lymph nodes
IIIC1 Pelvic nodes Lymph nodes >8 mm in short axis
IIIC2 Paraaortic nodes w/wo pelvic nodes Lymph nodes >10 mm in short axis
IV Bladder/bowel mucosa; or distant metastases
IVA Bladder/bowel mucosa Tumour disrupts bladder or bowel muscle and invades mucosa; not bullous
edema
IVB Metastases abdominal and extraabdominal; inguinal
lymph nodes
Tumour deposits at distal sites including peritoneal mets, bladder, bone liver mets,
and distal lymph node metastases
aAdapted from FIGO Commitee on Gynecologic cancers. FIGO classification of cancer of the vulva, cervix, and corpus uteri. International Journal of Gynecology
Obstetrics 2014; 115:97–98
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 Multiparametric approach combining T2WI, DWI
and dynamic Gd MRI will render the most
comprehensive approach to assess local tumour
spread. It is most useful if radiologist supervision
when images are obtained is not feasible or in less
experienced readers (Fig. 2).
 Cervical invasion is assumed when there is thinning or
focal disruption of the hypointense signal of the
cervical stroma and its continuity with the tumour.
Stromal invasion, particularly when subtle is best
identified in a plane perpendicular to the cervical canal.
 Invasion of the pelvic wall is suggested when the
distance between the tumour and the pelvic wall
including internal obturator muscle, levator ani,
piriformis muscle or iliac vessels is less than 3 mm.
 Rectum or bladder wall invasion is best evaluated in
the sagittal plane. Preservation of the fat plane
between tumour and bladder or rectum allows
reliable exclusion of stage IVA.
 In aggressive tumour histologies (type II) careful
assessment of the abdomen and pelvis for peritoneal
deposits is warranted (Fig. 5).
Fig. 3 Subserous tumour spread. Type II endometrial cancer (grade III) with subserous uterine growth (a, arrow). Transaxial T1WI demonstrates
hemogeneous structure with hemorrhage (b,*). Necrosis is seen on T1GD FS (c). Transaxial DWI (d) at the level of the primary tumour and above
(e) demonstrate high signal on b 1000. The focal osseous lesion with high signal on high b value image corresponds to a bone metastasis in
PET/CT (f)
Fig. 4 DWI to depict lymph nodes. Cancer of the endometrium originating from the distal corpus uteri with growth to the cervix (a and b,*).
Cervical stromal thinning displayed in a. Bilateral regional lymph nodes are well displayed on T2WI a, arrowheads) and on DWI. The lymph node
at the level of the aortic bifurcation (arrow) on sagittal T2WI (a) displaying high SI on DWI (c) was not metastatic at histology
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Key points in lymph node imaging in endometrial cancer
 Regional nodes are pelvic and paraaortic lymph
nodes. The latter may be the first manifestation of
lymphatic spread.
 The rate of lymph node metastases in low risk
cancers is very low (2.4 %). It rises with increasing
risk categories to 9 % resp. 24 % in intermediate
resp. high risk categories [5 ,11].
 Lymph nodes are easiest to depict on DWI due to
their high SI on the high b value image.
 As DWI is limited in predicting lymph node
metastases classical morphological criteria have to be
combined for characterization (Fig. 4). These include
short axis diameter of pelvic lymph nodes with > 8 mm
and abdominal lymph nodes > 10 mm. However,
smaller lymph nodes with low ADC, irregular
contours, with necrosis and clusters of lymph nodes
may also be called suspicious of metastases [20].
Pitfalls, challenges and how to overcome these
 Tumour involving more than half of the myometrial
thickness is staged as IB. The area of the uterine
cornua is physiologically thinner than the normal
myometrium. Hence, particularly, when it is
symmetrical invasion at this location should not be
overcalled.
 In atrophic uteri and in tumours isointense relative
to myometrium complementary problem solving
modalities should be performed complementary to
T2WI. In DWI the angulation along the uterus
should be identical to the T2W sequence. High
resolution 3D T1 WI at about 2–2.5 min after IV
contrast media application may be best able to solve
the problem [9].
 If the depth of myometrial invasion is equivocal on
T2WI and DWI, complementary GDT1 WI should
be applied [15] (Fig. 2).
 In thinning of the endometrium caused by tumouros
distension of the uterine cavity by expansively
growing cancers myometrial assessment may be
challenging [21]. Symmetry and smooth contours
favour stage IA.
 In endometrial cancer and coexisting adenomyosis
or atypical uterine leiomyomas the complementary
use of both DWI and Gd is advised to assess the
depth of myometrial invasion. Of note, both
adenomyosis and some leiomyomas may show
restricted diffusion, and leiomyomas may also be
hypervascular.
 Double angulation technique provides a true
orthogonal view of the uterus and may improve
assessment of myometrial invasion in rotated or
tilted uteri. Thus, the problem of volume averaging
artifacts can be reduced [15].
Fig. 5 Peritoneal spread in aggressive tumour histology. A broad-based endometrial mass is seen on transaxial and coronal T2WI (a, b). Gd T1WI also
demonstrates bilateral solid enhancing adnexal lesions (arrows, d) with only moderate ovarian enlargement. Further, omental nodules are displayed (*).
On the high b value image DWI demonstrates high signal intensity of the ovarian mass (arrow, c) and the peritoneal deposits (*, c). The histology of
type II endometrial cancer favours metastases. However histopathological proof is necessary for differentiation
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 In equivocal lymph nodes morphologic criteria
should be combined with functional information.
Enhancement pattern or ADC similar to the uterine
cancer support the diagnosis of metastasis
 To reduce pitfalls in interpretation in DWI the
findings should always be correlated with T2WI.
The optimal high b value varies from field strength
and vendors. It should be 800 mm/s [2] or more and
is optimal when the fluid in the urinary bladder
appears dark.
Clinically challenging constellations and how to aid with
imaging
Synchronous endometrial cancer and adnexal masses
Estrogen stimulation of the endometrium is a major
risk factor for type I endometrial cancer. Thus hor-
mone- active ovarian tumours and endometrial hyper-
plasia or endometrial cancer may be detected
simultaneously. Coexisting endometrial cancer is re-
ported in granulosa cell tumours and thecomas in 3–
25 % of cases [22]. In imaging granulosa cell tumours
may display a wide range from solid heterogeneous to
multicystic masses. In contrast, when thecomas dis-
play typical imaging features of well-delineated solid
masses with low SI in T2WI MRI allows a specific
diagnosis [23].
More challenging is the constellation of endometrial
cancer and imaging features of a malignant ovarian
mass. This may present both an independent ovarian
neoplasm or metastases from endometrial cancer.
Synchronous endometrial and epithelial ovarian can-
cer are reported in 5 % of patients with endometrial
cancer and in 10 % of patients with ovarian cancer
[4]. In endometroid cancers, synchronous ovarian
cancers are more likely to occur in premenopausal
age and often these may only be microscopic. The
rare clear cell ovarian cancer typically presenting as a
cystic mass with solid nodules protruding into the le-
sion may also be associated with endometrial cancer
[24]. In general, metastases to the ovaries seem more
likely to be found in type II endometrial cancer [25]
(Fig. 5). Further, metastases from endometrial cancer
rather than a second primary in the ovaries should be
suspected in bilateral ovarian involvement in small
size of the ovarian mass or in multinodularity of the
ovaries [26].
Uterine cancer of unknown origin- endometrial or
cervical cancer Usually prior to MRI staging the origin
of a uterine malignancy is known based upon clinical as-
sessment and/or obtained histology. However, in a small
subset of patients, e.g. one institution reported 3.2 %,
this remains uncertain [27]. At histology and even
immunohistochemically the differentiation of endomet-
rial from endocervical carcinoma may sometimes be
challenging [28]. In this constellation Radiology can as-
sist in defining the origin by analyzing imaging features
of the tumour and its local patterns of growth. Clinically,
this information is pivotal as treatment regimen differ
completely. In one study differentiation was feasible in
85 % (45/48) of cases [29]. Features favouring endomet-
rial cancer over cancer of the uterine cervix are: epicen-
ter of the mass is the endometrial cavity rather than
cervix, depiction of tumour growing within the endo-
metrial cavity or hypovascularity in arterial phase in
small tumour size [28] (Fig. 6). However, small cancers,
type II cancers or sarcoma may be hypervascular, but
the latter usually tend to be heterogeneous. Central ne-
crosis and per continuation bladder invasion or uterove-
sical fistulation favour the diagnosis of cervical cancer.
Fig. 6 Clinically adenocancer of unknown origin. Sagittal T2WI (a) shows a large tumour with the epicenter in the uterine corpus extending to
the external cervical os. Circumferential thinning of the cervical stroma is seen on the oblique transaxial section (b). There is no evidence of
involvement of the uterovesical ligaments or the bladder wall. All these findings favour the diagnosis of endometrial rather than cervical cancer
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Image interpretation
Reporting checklist Radiology reports may be provided
in a structured computer assisted report or on a free text
basis. Regardless of the format the following central ele-
ments have to be addressed: Lesion size, using diameters
at least assessed in two planes, size of the uterus in two
orthogonal planes and distension of the uterine cavity;
characteristics of the tumour (e.g. heterogeneity, haem-
orrhage, necrosis, hypervascularization). Further, exten-
sion of the tumour within the uterus (less or more than
half of the myometrium and cervical stroma) and exten-
sion to uterine surface or ovaries have to be notified.
Bladder and particularly rectosigmoid colon invasion
should be addressed. The status of lymph nodes should
be assessed. This includes allocation and size of suspi-
cious lymph nodes in the pelvis and retroperitoneum.
Other tumour-related findings to mention include dis-
tant metastases (e.g. peritoneal spread liver metastases
and lymph nodes) and urinary obstruction. Finally, find-
ings relevant for surgery, e.g. vascular variations of pelvic
and retroperitoneal vessels and other findings including
incidentalomas should be reported. Although a matter
of debate among radiologists, at our institution we add
the MRI stage as indicated by the findings in the end of
the report [9].
Conclusions
MRI is a potent imaging tool assisting to triage treat-
ment in women with endometrial cancer based on
multidisciplinary team consensus. The depth of myome-
trial invasion, cervical extension and lymph node metas-
tases present major findings to analyse in the staging
MRI. Thus, combined with the histological subtype MRI
renders crucial information for pretreatment risk stratifi-
cation. MRI assists in accurate treatment planning and
selection of patients who will profit from paraaortic
lymph node dissection. Radiologists have to be aware of
the differences in imaging and clinical features of the
two main types or endometrial cancer. Imaging tech-
nique can be optimized for endometrial cancer staging,
and advanced techniques allow improved accuracy of
local tumour spread. These may also alert to metastatic
sites difficult to assess with conventional MRI.
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